je.st
news
Tag: high
Vandals cause $300,000 damage to Portland, Ore., high school
2016-10-25 20:10:00| American School & University
Teens believed to be from other schools flooded a section of Roosevelt High School. read more
High Performance Beverage Co's Lemon/Lime Sports Drink - Product Launch
2016-10-25 15:05:00| Daily beverage news and comment - from just-drinks.com
High Performance Beverage Co has announced plans to launch a lemon/lime flavoured sports drink.
Tags: high
product
sports
performance
Large-scale study finds long-term exposure to air pollution linked to high blood pressure
2016-10-25 12:55:31| Green Car Congress
FDA Approves Mercks KEYTRUDA (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations
2016-10-25 00:04:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA is the Only Anti-PD-1 Therapy Approved in First-Line Treatment of Metastatic NSCLC; KEYTRUDA Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Expressed High Levels of PD-L1 FDA Also Approves a Labeling Update for KEYTRUDA for the Treatment of Patients with Metastatic NSCLC Whose Tumors Express PD-L1 (TPS of One Percent or More) With Disease Progression On or After Platinum-Containing Chemotherapy; Patients With EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression On FDA-Approved Therapy for These Aberrations Prior to Receiving KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA (pembrolizumab), the companys anti-PD-1 (programmed death receptor-1) therapy, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
High yields, low grain prices: Manage phosphorus and potassium wisely
2016-10-24 19:07:00| Corn & Soybean Digest
Yields are great but prices are low forcing cuts to be made in input costs. Soil sampling may be key in reducing phosphorus (P) and potassium (K) fertilizer application rates. read more
Sites : [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239] [240] [241] [242] [243] [244] [245] [246] next »